1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Cryomass Technologies
  6. News
  7. Summary
    CRYM   US22905K1051

CRYOMASS TECHNOLOGIES

(CRYM)
Delayed OTC Markets  -  05/16 03:56:32 pm EDT
0.3500 USD   -5.41%
05/12CRYOMASS TECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/12Cryomass Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02CRYOMASS TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

CRYOMASS TECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

05/12/2022 | 03:09pm EDT

Forward-Looking Statements

This quarterly report contains forward-looking statements. These statements
relate to future events or our future financial performance. In some cases, you
can identify forward-looking statements by terminology such as "may", "should",
"expects", "plans", "anticipates", "believes", "estimates", "predicts",
"potential" or "continue" or the negative of these terms or other comparable
terminology. These statements are only predictions and involve known and unknown
risks, uncertainties and other factors that may cause our or our industry's
actual results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements.



Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.




In this quarterly report, unless otherwise specified, our financial statements
are expressed in United States Dollars (US$) and are prepared in accordance with
United States generally accepted accounting principles. All references to
"common shares" refer to the common shares in our capital stock.



Unless expressly indicated or the context requires otherwise, the terms
"Cryomass Technologies," the "Company," "we," "us," and "our" refer to Cryomass
Technologies Inc.., a Nevada corporation, and, where appropriate, its wholly
owned subsidiaries.



General Overview


Cryomass Technologies Inc ("Cryomass Technologies" or the "Company") began as
Auto Tool Technologies Inc., which was incorporated under the laws of the State
of Nevada on May 10, 2011. The Company's name was changed to AFC Building
Technologies Inc. effective January 10, 2014. Effective April 26, 2018, the
Company changed its name to First Colombia Development Corp. Effective October
14, 2019, the Company changed its name to Redwood Green Corp. Effective
September 1, 2020, the Company changed its name to Andina Gold Corp. On July 15,
2021, the Company entered into a plan of merger with its wholly-owned
subsidiary, Cryomass Technologies Inc a Nevada corporation, for the purpose of
changing the name of the Company to Cryomass Technologies Inc. effective August
27, 2021. Our ticker symbol changed from AGOL to CRYM.



The Company's principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company's website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this prospectus.

The Company over its history has explored a number of different business opportunities.

On May 10, 2018, the Company acquired all the issued and outstanding share
capital of First Colombia Devco S.A.S. ("Devco") a Colombian company, and began
to establish various business ventures in Colombia in the agriculture and real
estate development, tourism, and infrastructure sectors before commencing to
phase them out in April 2019.



On July 1, 2019, the Company acquired 100% of the membership interests in
General Extract, LLC ("General Extract"), a Colorado limited liability company.
General Extract was founded in 2015 as an importer, distributor, broker and
postprocessor of hemp and hemp derivatives. The Company acquired all of the
issued and outstanding membership interests, including business plans and access
to contacts.



                                       19





On July 15, 2019, the Company, through its wholly owned subsidiary Good
Acquisition Co., entered into a Membership Interest Purchase Agreement to
acquire cannabis-related intellectual property and other assets of Critical Mass
Industries LLC DBA Good Meds ("CMI" and/or "Good Meds"), a Colorado limited
liability company ("CMI Transaction"). CMI is licensed by the Marijuana
Enforcement Division of Colorado Department of Revenue to produce cannabis and
cannabis products under its six licenses. These licenses allow for cultivation,
manufacturing of infused products and retail distribution. At the time the
Company entered into the Membership Interest Purchase Agreement, Colorado law
prohibited public companies, including the Company, from owning cannabis
licenses. Therefore, CMI spun off certain assets acquired by the Company. Under
the terms of the Membership Interest Purchase Agreement, CMI retained the
cannabis license, inventory and accounts receivable (the "Cannabis License
Assets") and continued to operate the cannabis business related to those assets.
In consideration for the transfer of the acquired assets, the Company delivered
13,553,233 shares of the Company common stock, in addition to $1,999,770 in
cash
to CMI.



Effective December 31, 2021, we entered into a restated and amended
administrative services agreement, terminated our license and marketing
agreements, and restated the asset purchase agreement with CMI and affiliates.
As a result of these agreements, we disposed of all CMI-related assets and
extinguished any and all related obligations. For clarity, we have no management
or operations decision-making right or responsibility, nor any access to future
economic benefits from operation of the assets. Therefore, upon commencing these
agreements, we determined that CMI no longer qualifies as a variable interest
entity ("VIE") as of December 31, 2021.



Good Meds, the operating unit of CMI, is based in Denver, CO, and operates in a
60,000-square-foot cultivation and processing facility. This facility produces
cannabis for sale as dry flower and biomass input for processing into
Marijuana-Infused Products ("MIP"), such as live resin, wax and budder. Good
Meds also owns and operates two medical cannabis dispensaries located in
Lakewood, CO and Englewood, CO. The business has been in operation since 2009.



Beginning in March 2020, an evaluation of various strategic alternatives was
followed by the decision to sell the Colorado-based assets and refocus its
attention on unique opportunities for gold exploration in Colombia. In August
2020, the Company established a wholly owned Colombian subsidiary, Andina Gold
Colombia SAS for this purpose. In December 2020, due to the death of the top
geologist exploring opportunities on behalf of the Company, and the effects of
the ongoing Coronavirus pandemic, the Company determined that pursuit of gold
exploration in Colombia was no longer a practical alternative.



On June 22, 2021, the Company entered into an Asset Purchase Agreement with
Cryocann USA Corp, a California corporation ("Cryocann"), pursuant to which
Company acquired substantially all the assets of Cryocann. The aggregate
purchase price was $3,500,000 million in cash and 10,000,000 shares of Company
common stock As part of the Cryocann Acquisition, we retained both Cryocann
employees, who have expert knowledge of the industry, related participants,
customers and the acquired patented technology. Under their employment
agreements, each employee may receive compensation if specific performance
targets are met in association with our future operating performance when the
Cryocann technology enters the market. The technology and assets acquired from
Cryocann are operated from the Company's subsidiary, Cryomass LLC. The patented
cryo-mechanical technology is for the separation of plant materials in the
harvesting of hemp and cannabis, and potentially other high value crops such as
hops. We believe this technology will reduce processing costs and increases the
quality of extracted compounds. We are exploring the application of the
underlying technology to a broad range of industries that handle high-value
materials and that could benefit from our precision capture methods. We
anticipate that cannabis and hemp will be the first in a series of such
industries.



To develop and commercialize the technology, we contracted with an independent
engineering and manufacturing firm to refine the design of our cryo-mechanical
system for the handling of harvested hemp, cannabis and other high-value plants.
The system exploits CryoMass's U.S.-patented process for the controlled
application of liquid nitrogen to stabilize and separate the structural elements
of gross plant material. The device currently under development is scaled for
highway transportability and is being optimized for the low-cost collection of
fully intact hemp and cannabis trichomes. It can be used within minutes after
plants have been cut and can also efficiently capture trichomes from fresh
frozen or even dried plant parts, including trim. The device's through-put
capacity is expected to be approximately 600 kilograms of gross plant material
per hour. The advanced design for the equipment has been completed, and testing
of a prototype machine is currently underway. The engineering and manufacturing
firm has indicated that it has the capacity to build 10 to 15 such devices
per
month.



                                       20




In November 2021, we retained a second engineering and manufacturing firm to independently develop a separate machine design that applies our patented process. This work is now complete.




The first functional "beta" machine is expected to be fully field-tested during
mid-2022. In the same time-frame, we expect to commission the build of the first
production-run system and to deploy both machines in commercial scale operations
by the end of the third quarter, 2022, including revenue generation.



Management believes the CryoMass system will deliver a compelling combination of
cost and time savings while enhancing product quality and quantity for
largescale cultivators and processors of hemp and cannabis. The use of
a CryoMass system - which can be trucked to and operated on the fields of most
large hemp and cannabis growers or be permanently installed at a user's
processing facility - should eliminate many of the costs that come with
traditional practices, especially the labor, fuel and capital costs of drying
and curing hemp or cannabis that is grown for the extraction of end
products. With traditional practices, harvested plants are transported to a
specially constructed drying house and then treated for a week or longer under
controlled conditions of temperature and humidity. It's a costly method. With
our system, harvested plants are simply fed into the front end of
a CryoMass machine, and minutes later fully intact trichomes are collected at
the back end of the machine. With traditional practices and their seven-to-ten
days of handling and drying, a large share of a plant's valuable trichomes break
off and are lost. Then the remaining trichomes are damaged by long exposure to
oxygen and by the evaporation of their volatile terpenes. The CryoMass system,
on the other hand, stabilizes and collects fully intact trichomes at harvest,
leaving no opportunity for such wasteful loss. Field-captured trichomes are the
cleanest element of a hemp or cannabis plant because, unlike the rest of the
plant, trichomes do not readily take up heavy metals, pesticides or other common
soil contaminants. As a product for end-users, field-captured trichomes are
closest to being contaminant free. As feedstock for manufacturers of extracts
and oils, they are the key to the purest products possible.



Because the trichomes collected with CryoMass technology represent only 10% or
so of a plant's weight and volume, they are cheaper to ship and store than gross
plant material. For the same reason and because trichomes are free of the waxes
and other unwanted materials found in the rest of the plant, processing
trichomes into oils and extracts can be far quicker, cheaper and easier than
processing gross plant material. Even trichomes captured from dried or frozen
plant parts deliver this cost-saving advantage to processors of oils and
extracts. The three-dimensional advantage achievable with the CryoMass system -
first-stage cost savings, product enhancement and downstream cost savings - can
as much as double a crop's wholesale value. And in some jurisdictions, users may
enjoy a reduction in excise taxes levied on cannabis and hemp harvests, which
typically are tied to the gross weight of hemp or cannabis that is removed
from
the field.



Production and processing of hemp and cannabis is a huge, worldwide industry. In
the U.S., for example, the wholesale value of the cannabis crop from just the 11
states permitting adult-use and medical cannabis exceeds $6 billion
annually.1 Growth in the U.S. and in the worldwide market is likely fed in part
by the growing acceptance of medicinal cannabis products and anticipated
legislative changes in various jurisdictions worldwide.



And that may only be chapter one of the Company's story. Several other
high-value plants, including species that are important for health and wellness
products, wrap their valuable elements in trichomes. The technology we are
developing for hemp and cannabis may have profitable application to those other
species as well. We intend to find out.



In September, we were granted an additional patent for our process from the Chinese Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and several other international jurisdictions.



                                       21





On November 17th we announced the completion of a $10.3 million equity
financing. The financing and the earlier conversion of substantially all the
company's debt into common stock left the Company with a strong balance sheet
and adequate resources for our planned business development during the coming
twelve months. In connection with the financing, 1,010,000 shares and 760,000
shares of CryoMass Technologies common stock were purchased by CEO Christian
Noël and Chairman of the Board Delon Human, respectively, either individually or
through entities controlled by them.



Update on COVID-19



In December 2019, a novel strain of coronavirus was reported to have surfaced in
Wuhan, China, which has spread throughout the world, including the United
States. On January 30, 2020, the World Health Organization declared the outbreak
of COVID-19 a "Public Health Emergency of International Concern," and on March
11, 2020, it characterized the outbreak as a "pandemic". The impact of COVID-19
developments and uncertainty with respect to the economic effects of the
pandemic has introduced significant volatility in the financial markets.



To date, COVID-19 has surfaced in nearly all regions around the world and
resulted in travel restrictions, both domestic and international, closing of
borders and business slowdowns or shutdowns in affected areas. As a
result, COVID-19 has impacted the Company's business. Although deemed an
essential business during the pandemic, many dispensaries and cannabis
manufacturers have suspended or reduced operations on a temporary basis due to
matters associated with COVID-19.



The COVID-19 pandemic and responses to this crisis, including actions taken by
federal, state and local governments, have had an impact on the operations of
the Company, including, without limitation, the following: reduced staffing due
to employee suspected conditions and social distancing measures; constraints on
productivity; management and staff non-essential business-related travel was
constrained due to stay-at-home orders; some employees have shifted to remote
work resulting in loss of productivity; consumers visiting dispensaries operated
under license impacted by stay-at-home orders. Management continues to monitor
the COVID-19 pandemic situation and federal, state and local recommendations and
will provide updates as appropriate.



Our Current Business



Our business portfolio includes the accounts of Cryomass LLC (formerly known as
General Extract), which is controlled by the Company through its 100% ownership
interest. The Company dissolved its previously reported VIE relationship with
Critical Mass Industries Inc., such that we no longer report the VIE as
discontinued operations held for sale.



On June 23, 2021, the Company consummated purchase of assets of Cryocann USA
Corp through its wholly-owned subsidiary Cryomass LLC. We are currently
finalizing research and development work of our patented technology. We intend
to begin commercial-scale testing of the system prototype in the first half of
2022 and plan to target specific markets and industries to employ this
ground-breaking technology.



To develop and commercialize the technology, we contracted with an independent
engineering and manufacturing firm to refine the design of our cryo-mechanical
system for the handling of harvested hemp, cannabis and other high-value plants.
The system exploits CryoMass's U.S.-patented process for the controlled
application of liquid nitrogen to stabilize and separate the structural elements
of gross plant material. The device currently under development is scaled for
highway transportability and is being optimized for the low-cost collection of
fully intact hemp and cannabis trichomes. It can be used within minutes after
plants have been cut and can also efficiently capture trichomes from fresh
frozen or even dried plant parts, including trim. The device's through-put
capacity is expected to be approximately hundreds of kilograms of gross plant
material per hour. The advanced design for the equipment has been completed,
and testing of a prototype machine is currently underway. The engineering and
manufacturing firm has indicated that it has the capacity to build 10 to 15
such
devices per month.



                                       22







The first functional "beta" machine is expected to be fully field-tested during
mid-2022. In the same time-frame, we expect to commission the build of the first
production-run system and to deploy both machines in commercial scale operations
by the end of the third quarter, 2022, including revenue generation.



Management believes the CryoMass system will deliver a compelling combination of
cost and time savings while enhancing product quality and quantity for
largescale cultivators and processors of hemp and cannabis. The use of
a CryoMass system - which can be trucked to and operated on the fields of most
large hemp and cannabis growers or be permanently installed at a user's
processing facility - should eliminate many of the costs that come with
traditional practices, especially the labor, fuel and capital costs of drying
and curing hemp or cannabis that is grown for the extraction of end
products. With traditional practices, harvested plants are transported to a
specially constructed drying house and then treated for a week or longer under
controlled conditions of temperature and humidity. It's a costly method. With
our system, harvested plants are simply fed into the front end of
a CryoMass machine, and minutes later fully intact trichomes are collected at
the back end of the machine. With traditional practices and their seven-to-ten
days of handling and drying, a large share of a plant's valuable trichomes break
off and are lost. Then the remaining trichomes are damaged by long exposure to
oxygen and by the evaporation of their volatile terpenes. The CryoMass system,
on the other hand, stabilizes and collects fully intact trichomes at harvest,
leaving no opportunity for such wasteful loss. Field-captured trichomes are the
cleanest element of a hemp or cannabis plant because, unlike the rest of the
plant, trichomes do not readily take up heavy metals, pesticides or other common
soil contaminants. As a product for end-users, field-captured trichomes are
closest to being contaminant free. As feedstock for manufacturers of extracts
and oils, they are the key to the purest products possible.



Because the trichomes collected with CryoMass technology represent only 10% or
so of a plant's weight and volume, they are cheaper to ship and store than gross
plant material. For the same reason and because trichomes are free of the waxes
and other unwanted materials found in the rest of the plant, processing
trichomes into oils and extracts can be far quicker, cheaper and easier than
processing gross plant material. Even trichomes captured from dried or frozen
plant parts deliver this cost-saving advantage to processors of oils and
extracts. The three-dimensional advantage achievable with the CryoMass system -
first-stage cost savings, product enhancement and downstream cost savings - can
as much as double a crop's wholesale value. And in some jurisdictions, users may
enjoy a reduction in excise taxes levied on cannabis and hemp harvests, which
typically are tied to the gross weight of hemp or cannabis that is removed
from
the field.


Results of Operations for the Three Months Ended March 31, 2022 and 2021




Our operating results for the three months ended March 31, 2022 and 2021 are
summarized as follows:



                                             For the Three Months Ended
                                                      March 31,                           Change
                                                2022              2021           Dollars        Percentage
Net sales                                  $            -     $          -     $          -               0 %
Cost of goods sold, inclusive of
depreciation                                            -                -                -               0 %
Gross profit                                            -                -                -               0 %
Total operating expenses                        2,127,790          995,704        1,131,820             114 %
Loss from operations                           (2,127,790 )       (995,704 )     (1,131,820 )           114 %
Total other expenses                              (24,515 )       (167,839 )        141,862             -85 %
Net loss from continuing operations,
before taxes                                   (2,152,305 )     (1,163,543 )       (989,958 )            85 %
Income taxes                                            -                -                -               0 %

Net loss from continuing operations $ (2,152,305 ) $ (1,163,543 ) $ (989,958 )

            85 %
Net income / (loss) from disc.
operations, net of tax                     $            -     $    116,616     $   (116,616 )          -100 %
Net loss                                   $   (2,152,305 )   $ (1,046,927 )   $  1,106,574             106 %




                                       23




Our operating results for the three months ended March 31, 2022 and 2021, relating to our variable interest entity, CMI, are classified as discontinued operations above and summarized as follows:



                                                 For the Three Months Ended
                                                          March 31,                          Change
                                                   2022              2021           Dollars        Percentage
Net sales                                       $        -       $  1,695,925     $ (1,695,925 )          -100 %
Cost of goods sold, inclusive of depreciation            -          1,118,735       (1,118,735 )          -100 %
Gross profit                                             -            577,190         (577,190 )          -100 %
Total operating expenses                                 -            431,310         (431,310 )          -100 %
Gain from operations                                     -            145,880         (145,880 )          -100 %
Total other expenses                                     -            (29,264 )        (29,264 )          -100 %
Net income, before taxes                                 -            116,616         (116,616 )          -100 %
Income taxes                                             -                  -                -            -100 %
Net income                                      $        -       $    116,616     $   (116,616 )          -100 %



Net Sales and Cost of Goods Sold




There were no net sales related to continuing operations for the three months
ended March 31, 2022 and 2021. There were no net sales related to CMI for the
three months ended March 31, 2022. CMI net sales were $1,695,925 for the three
months ended March 31, 2021, of which $1,130,504 was related to medical retail,
$556,310 was related to medical wholesale, $9,010 was related to recreational
wholesale, and $101 was related to other revenues. In the fourth quarter of
2020, CMI decided to stop growing recreational product in order to create
additional space to grow more medical product. This change resulted in decreased
revenue from recreational wholesale and increased revenue in both medical retail
and medical wholesale. The overall decrease in CMI net sales for the three
months ended March 31, 2022 compared to the three months ended March 31, 2021
was $1,695,925, or 100%, which is attributable to the Company's disposal of its
discontinued operations as of December 31, 2021.



There were no cost of goods sold related to continuing operations for the three
months ended March 31, 2022 and 2021. CMI's cost of goods sold were $0 and
$1,118,735 for the three months ended March 31, 2022 and 2021, respectively,
representing a decrease of $1,118,735 or 100%. This decrease is attributable to
the Company's disposal of its discontinued operations as of December 31, 2021.



Operating Expenses



Operating expenses encompass personnel costs, research and development, general
and administrative expenses, and legal and professional fees. Total operating
expenses were $2,127,790 for the three months ended March 31, 2022 as compared
to $995,704 for the three months ended March 31, 2021. The decrease of
$1,132,086, or 114%, was primarily attributable to the following changes in
operating expenses of:



  ? Legal and professional fees - $1,232,737 increase




  ? General and administrative - $101,121 decrease




The increase of $1,232,471, or 547%, in legal and professional fees is primarily
due to the fact that the Company incurred significant costs related to investor
relations market awareness activities during the three months ending March 31,
2022. The decrease of $101,121, or 26%, in general and administrative expenses
is primarily due to the fact that the Company incurred additional stock-based
compensation expense during the three months ending March 31, 2021 related to
Chris Hansen's separation agreement and accelerated vesting of RSU's



                                       24





CMI operating expenses encompass personnel costs, sales and marketing, general
and administrative, legal and professional fees, and amortization expense. Total
operating expenses for CMI were $0 and $431,310 for the three months ending
March 31, 2022 and 2021, respectively, representing a decrease of $431,310
or
100%.



Other Expense



Other expense for the three months ending March 31, 2022 consisted of $36,023
interest expense - net and $11,508 gain on foreign exchange. Other expense for
the three months ending March 31, 2021 consisted of $202,609 interest expense
and $34,770 gain on foreign exchange. The decrease in interest expense was a
result of the Company paying off a significant amount of its debt throughout
2021. The gain on foreign exchange relates to a payable agreement with Cryomass
LLC's supplier.


CMI had no other expense for the three months ending March 31, 2022. CMI's other expense during the three months ending March 31, 2021 consisted of $29,264 interest expense, which primarily relates to the related party note. This decrease is attributable to the Company's disposal of its discontinued operations as of December 31, 2021.



Net Loss



For the foregoing reasons, we had a net loss of $2,152,305 for the three months
ending March 31, 2022, or $0.01 net loss per common share - basic and diluted,
compared to a net loss of $1,046,927 for the three months ending March 31, 2021,
or $0.01 net loss per common share - basic and diluted.



Liquidity, Capital Resources and Cash Flows




During 2021 Q2 and Q3, the Company obtained a total of $4,900,000 cash through a
convertible debt unit offering consisting of a convertible note and a warrant to
purchase shares. These funds are available to cover operating expenses while
exploring new business opportunities. On June 23, 2021, the Company consummated
purchase of assets of Cryocann USA Corp.



As of March 31, 2022, the Company had working capital of $2,302,548 and
cash balance of $3,594,275. The Company estimates that it needs approximately
$3,000,000 to cover overhead costs plus an additional $500,000-$2,000,000 to
support the capital expenditures and operations and growth of the assets
acquired from CryoCann USA Corp, over the next twelve months. Management
believes it has sufficient cash available, based on proceeds from two private
placements completed during the previous year to support the anticipated level
of operations for the foreseeable future.



COVID-19 has resulted in, and may continue to result in, significant disruption
of financial markets, which may reduce the Company's ability to access capital
or its customers' ability to pay the Company for past or future purchases, which
could negatively affect the Company's liquidity. The Company believes that the
cash balances and cash from operations will be sufficient to satisfy its cash
needs for the next few months until it can obtain new long-term financing or
other sources of capital. If we are unable to attain additional financing, we
will have to seek additional strategic alternatives and relief from our
additional liabilities accumulated during COVID-19.



The impact of COVID-19 developments and uncertainty with respect to the economic
effects of the pandemic have introduced significant volatility in the financial
markets. The uncertainties associated with COVID-19 related to our industry
present risk and doubt about the Company's ability to continue as a going
concern.



Going Concern


Management believes it has sufficient cash available to support an anticipated level of operations for at least 12 months following the date of this report.



                                       25





Capital Resources



The following table summarizes total current assets, liabilities and working capital for the periods indicated:



                       March 31,       December 31,
                         2022              2021

Current assets $ 3,667,453 $ 6,530,222 Current liabilities 1,364,905 1,882,419 Working capital $ 2,302,548 $ 4,647,803

As of March 31, 2022 and December 31, 2021, we had a cash balance of $3,594,275 and $5,772,839, respectively.

© Edgar Online, source Glimpses

All news about CRYOMASS TECHNOLOGIES
05/12CRYOMASS TECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/12Cryomass Technologies Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/02CRYOMASS TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
05/02Cryomass technologies begins trials of user-ready equipment
PR
05/02Cryomass Technologies Begins Trials of User-Ready Equipment
CI
03/28CRYOMASS TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
03/28Cryomass Technologies Inc. Reports Earnings Results for the Full Year Ended December 31..
CI
01/18CRYOMASS TECHNOLOGIES, INC. : Change in Directors or Principal Officers, Regulation FD Dis..
AQ
01/18Cryomass technologies elects simon langelier to board of directors
PR
01/18Cryomass Technologies Inc. Elects Simon Langelier to Board of Directors
CI
More news
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 74,2 M 74,2 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float -
Chart CRYOMASS TECHNOLOGIES
Duration : Period :
Cryomass Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Christian NoŰl Chief Executive Officer & Director
Philip Blair Mullin Treasurer, Chief Financial & Accounting Officer
Delon Human Chairman
Mario Gobbo Independent Director
Mark Radke Independent Director